by Marisa Wexler, MS | Feb 12, 2026 | Myeloma News
Nuvation Bio expanded a trial testing its experimental therapy, safusidenib, in people with certain forms of glioma that carry an IDH1 mutation, transitioning the study from a Phase 2 to a pivotal Phase 3 trial. “Following discussions with regulatory agencies,...
by Marisa Wexler, MS | Feb 11, 2026 | Myeloma News
In an early clinical trial in the U.S., most women with hard-to-treat ovarian cancer given a low dose of cell therapy candidate liraltagene autoleucel, known for short as lira-cel, lived longer than they were expected to, according to new data announced by developer...
by MM360 Staff | Feb 11, 2026 | Publications
Cardiooncology. 2026 Feb 10. doi: 10.1186/s40959-025-00435-1. Online ahead of print. NO ABSTRACT PMID:41664246 | DOI:10.1186/s40959-025-00435-1
by MM360 Staff | Feb 11, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by Marisa Wexler, MS | Feb 10, 2026 | Myeloma News
Anito-cel (anitocabtagene autoleucel), a cell therapy in clinical development as a potential treatment for myeloma, may be less likely to cause side effects than similar, approved myeloma cell therapies, according to a preclinical study. Arcellx, which is developing...
